deferasirox has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, S; Fujisawa, K; Harima, H; Kaino, S; Matsumoto, T; Sakaida, I; Shinoda, S; Takami, T; Yamamoto, N; Yamasaki, T | 1 |
| Fujisawa, K; Harima, H; Kaino, S; Matsumoto, T; Sakaida, I; Shinoda, S; Takami, T; Yamamoto, N; Yamasaki, T | 1 |
2 other study(ies) available for deferasirox and Pancreatic Neoplasms
| Article | Year |
|---|---|
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Topics: cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Deferasirox; Humans; In Vitro Techniques; Iron Chelating Agents; Microarray Analysis; Neoplasm Invasiveness; Pancreatic Neoplasms; rac1 GTP-Binding Protein | 2020 |
Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deferasirox; Flow Cytometry; Humans; Immunohistochemistry; Iron Chelating Agents; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2016 |